Lipella Pharmaceuticals (LIPO) Competitors $0.63 -0.09 (-12.92%) As of 01:06 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIPO vs. TXMD, CSCI, ABP, TRIB, SNPX, GOVX, BCDA, ATNF, IMCC, and IBIOShould you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include TherapeuticsMD (TXMD), COSCIENS Biopharma (CSCI), Abpro (ABP), Trinity Biotech (TRIB), Synaptogenix (SNPX), GeoVax Labs (GOVX), BioCardia (BCDA), 180 Life Sciences (ATNF), IM Cannabis (IMCC), and iBio (IBIO). These companies are all part of the "pharmaceutical products" industry. Lipella Pharmaceuticals vs. Its Competitors TherapeuticsMD COSCIENS Biopharma Abpro Trinity Biotech Synaptogenix GeoVax Labs BioCardia 180 Life Sciences IM Cannabis iBio Lipella Pharmaceuticals (NASDAQ:LIPO) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk. Is LIPO or TXMD more profitable? TherapeuticsMD has a net margin of -114.07% compared to Lipella Pharmaceuticals' net margin of -988.83%. TherapeuticsMD's return on equity of -7.86% beat Lipella Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Lipella Pharmaceuticals-988.83% -224.08% -172.88% TherapeuticsMD -114.07%-7.86%-5.46% Which has more risk & volatility, LIPO or TXMD? Lipella Pharmaceuticals has a beta of -0.08, meaning that its share price is 108% less volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Which has better valuation and earnings, LIPO or TXMD? TherapeuticsMD has higher revenue and earnings than Lipella Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLipella Pharmaceuticals$536.36K5.22-$5.02M-$4.08-0.15TherapeuticsMD$1.76M7.82-$2.18MN/AN/A Do insiders and institutionals hold more shares of LIPO or TXMD? 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by insiders. Comparatively, 2.3% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media favor LIPO or TXMD? In the previous week, Lipella Pharmaceuticals and Lipella Pharmaceuticals both had 1 articles in the media. TherapeuticsMD's average media sentiment score of 1.89 beat Lipella Pharmaceuticals' score of 0.59 indicating that TherapeuticsMD is being referred to more favorably in the news media. Company Overall Sentiment Lipella Pharmaceuticals Positive TherapeuticsMD Very Positive SummaryTherapeuticsMD beats Lipella Pharmaceuticals on 8 of the 10 factors compared between the two stocks. Get Lipella Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIPO vs. The Competition Export to ExcelMetricLipella PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.80M$3.07B$5.70B$9.51BDividend YieldN/A2.36%4.69%4.01%P/E Ratio-0.1521.0428.0720.05Price / Sales5.22284.46448.5799.42Price / CashN/A42.7636.2258.56Price / Book0.398.378.665.87Net Income-$5.02M-$55.19M$3.25B$258.55M7 Day Performance-16.40%5.89%4.20%2.23%1 Month Performance-28.02%17.63%10.82%12.76%1 Year Performance-80.16%5.09%34.70%19.36% Lipella Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIPOLipella Pharmaceuticals1.7596 of 5 stars$0.63-12.9%N/A-78.8%$2.80M$536.36K-0.154Gap UpTXMDTherapeuticsMD0.435 of 5 stars$1.15-1.3%N/A-36.7%$13.25M$1.84M0.00420Gap DownCSCICOSCIENS BiopharmaN/A$4.15-1.1%N/AN/A$13.06M$9.59M-0.7120Positive NewsGap DownABPAbproN/A$0.21-5.6%$4.00+1,764.8%N/A$13.04M$180K0.0015Positive NewsGap UpTRIBTrinity Biotech0.8311 of 5 stars$0.71-1.3%N/A-77.5%$12.83M$61.56M-0.24480News CoverageSNPXSynaptogenix0.0429 of 5 stars$9.21-8.9%N/A+130.6%$12.80MN/A-0.914GOVXGeoVax Labs1.8955 of 5 stars$0.80-2.0%$8.88+1,004.8%-68.5%$12.80M$3.95M-0.2210Upcoming EarningsBCDABioCardia3.4971 of 5 stars$2.25-3.8%$25.00+1,011.1%-18.7%$12.71M$60K-0.9940Positive NewsATNF180 Life Sciences1.0568 of 5 stars$2.13-24.4%N/A-5.3%$12.50MN/A-0.147Positive NewsEarnings ReportGap UpHigh Trading VolumeIMCCIM Cannabis0.2356 of 5 stars$3.03-0.3%N/A+29.3%$12.24M$39.44M-4.73340Positive NewsGap DownIBIOiBio1.2553 of 5 stars$0.73+0.2%$5.00+586.8%-65.8%$12.06M$375K0.00100 Related Companies and Tools Related Companies TXMD Competitors CSCI Competitors ABP Competitors TRIB Competitors SNPX Competitors GOVX Competitors BCDA Competitors ATNF Competitors IMCC Competitors IBIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIPO) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipella Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipella Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.